Index

abdominal pregnancy,
case reports 583
diagnosis 584
hemorrhage from 583–6
incidence 584
timing of intervention 584
abdominal wall, bleeding from during cesarean section 448

Index

acute fatty liver of pregnancy
acute hemolytic transfusion reaction
acute normovolemic hemodilution
acute uterine inversion
ADAMTS 13
adherent placenta, see placenta accreta, placenta increta, placenta percreta
Afghanistan, misoprostol use in
amniotic fluid
angiogram, arterial anatomostic system between vaginal and uterine arterial systems
false aneurysm
proof of pseudoaneurysm
pseudoaneurysm of uterine artery
animal studies of pneumatic anti-shock garments
antenatal PPH prevention
antepartum hemorrhage and PPH risk
anti-shock garments, G-suit
history of
medical anti-shock trousers
non-pneumatic anti-shock garment
pneumatic anti-shock garment

analgesia
antenatal correction
blood transfusion refusal care pathway
anaphylaxis
antepartum hemorrhage and PPH risk
anastomoses, between uterine and vaginal arteries
between uterine arteries with arteries to lower ureters
major pelvic
of internal iliac artery
subplacental uterine network
tying of uterine and ovarian anastomoses
uterine anatomostic system
anatomy,
of internal iliac artery
for internal iliac artery ligation
of uterine arteries
pelvic vessels
surgical for placenta accreta management
vascular supply of pelvis

anemia,
antenatal correction
delayed clamping of cord and reduction
management in women refusing blood transfusion
management postpartum in Jehovah’s Witnesses

anastomoses,
between uterine and vaginal arteries
management

angiology,
arterial anatomostic system between vaginal and uterine arterial systems
false aneurysm
proof of pseudoaneurysm
pseudoaneurysm of uterine artery
animal studies of pneumatic anti-shock garments
antenatal PPH prevention
antepartum hemorrhage and PPH risk
anti-shock garments, G-suit
history of
medical anti-shock trousers
non-pneumatic anti-shock garment
pneumatic anti-shock garment

appendix

acute fatty liver of pregnancy
acute hemolytic transfusion reaction
acute normovolemic hemodilution
acute uterine inversion
ADAMTS 13
adherent placenta, see placenta accreta,
placenta increta, placenta percreta
Afghanistan, misoprostol use in
amniotic fluid
angiogram, arterial anatomostic system between vaginal and uterine arterial systems
false aneurysm
proof of pseudoaneurysm
pseudoaneurysm of uterine artery
animal studies of pneumatic anti-shock garments
antenatal PPH prevention
antepartum hemorrhage and PPH risk
anti-shock garments, G-suit
history of
medical anti-shock trousers
non-pneumatic anti-shock garment
pneumatic anti-shock garment

analgesia,
antenatal correction
blood transfusion refusal care pathway
anaphylaxis
antepartum hemorrhage and PPH risk
anastomoses, between uterine and vaginal arteries
between uterine arteries with arteries to lower ureters
major pelvic
of internal iliac artery
subplacental uterine network
tying of uterine and ovarian anastomoses
uterine anatomostic system
anatomy,
of internal iliac artery
for internal iliac artery ligation
of uterine arteries
pelvic vessels
surgical for placenta accreta management
vascular supply of pelvis

anemia,
antenatal correction
delayed clamping of cord and reduction
management in women refusing blood transfusion
management postpartum in Jehovah’s Witnesses

anastomoses,
between uterine and vaginal arteries
management

analgesia
antenatal correction
blood transfusion refusal care pathway
anaphylaxis
antepartum hemorrhage and PPH risk
anastomoses, between uterine and vaginal arteries
between uterine arteries with arteries to lower ureters
major pelvic
of internal iliac artery
subplacental uterine network
tying of uterine and ovarian anastomoses
uterine anatomostic system
anatomy,
of internal iliac artery
for internal iliac artery ligation
of uterine arteries
pelvic vessels
surgical for placenta accreta management
vascular supply of pelvis

anemia,
antenatal correction
delayed clamping of cord and reduction
management in women refusing blood transfusion
management postpartum in Jehovah’s Witnesses

anastomoses,
between uterine and vaginal arteries
management
use for abdominal pregnancy 585
antibiotic use in secondary PPH 469
anticoagulant therapy,
  during pregnancy and peripartum 206–8
epidural anesthesia and 207
antifibrinolytic therapy 36
antiphospholipid syndrome 201
aortic compression 6
FIGO guidelines on 613
intraoperative 10
arterial blood pressure measurement 76
arterial embolization 5
  for cervical and vaginal vault tears 195
  for supravaginal hematoma 197
  in secondary PPH 470
selective during operative delivery
  of infant in placenta accreta 255
use in Japan 171
arteriovenous malformations 495
artery, see specific arteries by name
Asia, severe acute maternal morbidity in
  see specific arteries by name
Australia,
  accurate PPH rate determination 152
  hysterectomy for secondary PPH in 470
  maternal morbidity 137
  severe acute maternal morbidity in 507
autologous blood transfusions 577–82
  use in Jehovah’s Witnesses 590
autopsy,
  after PPH 496
  litigation after lack of 532
B-Lynch compression suture,
  FIGO guidelines on 616
technique 434–6, 438
Bakri balloon 369, 370, 378, 379, 387–96
deflation regimen 391
insertion 372
mechanism of action 373
method of insertion 390
methodological parameters of use 389
quality Doppler profile 92
selection of 372
study results with 371
success rate 391
balloon tamponade 369–75
  balloon–uterus interface 374
  complications 409
devices for obstetric hemorrhage
  equipment tray 315
  FIGO guidelines on 615
  mechanism of action 373
  occlusion by 404
  placement of 408
  pressure–volume relationships 374
  uterine-specific cf non-specific
  balloons 387
  uterine specific 369
  uterovaginal balloon system 458–460
Bangladesh,
  blood loss assessment by mat 354, 558
  hydrostatic condom catheter 379
misoprostol use in 286
Belffort–Dildy Obstetrical Tamponade
  System 460
Belgium, accurate PPH rate
determination in 154
Benin, active management of third stage
  of labor in 123
Bernard–Soulier syndrome 208
bimanual compression of uterus 434
FIGO guidelines on 613
biochemical markers for placenta accreta
  248
biologically topical hemostatic
  agents 481–5
bipartite placenta 236
bipedal locomotion and PPH 194
bladder,
  adherent placenta 10
  injuries and ventouse delivery 5
blood component administration 38
blood loss,
  accurate estimation,
  BRASSS-V drape 81, 84–6, 134, 557
  reduced severe acute maternal morbidity and 508
  assessing 73
  assessment pitfalls 81–86
  before and after anti-shock garment use 335
  calibrated drapes cf visual assessment
  86
  causes of excessive 448
  classification of PPH based on 129
  clinical estimation 82
determination and comparison of
  studies 133
direct collection of 83–6
during placenta accreta surgery 268
  estimation from kanga 83, 353, 557
  in active management cf expectant
  105
  inaccurate estimation and maternal
  mortality 164
  measurement of and comparison of
  studies 134
  mechanism of action of anti-shock
  garments in 319
  non-pneumatic anti-shock garment
  for 318, 337
  normal loss during delivery 81
  physiological adaptations for 82
  rapidity 129
  visual estimation 71
  volume deficit 130
blood mat 354, 558
blood products,
  see transfusion
blood supply,
  S1 and S2 in placental invasion 267
blood transfusion, see transfusion
blood volume 73
blunt abdominal trauma 189–91
body mass index (BMI),
  external abdominal pressure and 336
  PPH incidence and 156
  PPH risk and 139
bowel obstruction and fibrin sealants 484
Brace suture technique 433, 452
bradykinin 581
brain size,
  early delivery of humans of other
  primates 59
PPH and 55
Brandt–Andrews technique for AMTSL
  134
BRASSS-V drape™ 81, 84–6, 134, 557
  breast milk 362
breathing management 520
broad ligament arteries, prepregnancy
  hemodynamics 179
BT-Cath balloon 369
calibrated drapes 84–6
Canada,
  accurate PPH rate determination
  153
  B-Lynch suture compression suture
  use in 438
  maternal morbidity 137
  near miss data collection in 148
  planned home deliveries in 572
  severe acute maternal morbidity in
  501, 506
carboprost, for uterine atony
  357
  side-effects 357
  cardiac output measurement 521
care plan for women in labor refusing
  blood transfusion 597
case reports 546–8
  abdominal pregnancy hemorrhage
  treatment 583–6
catheterization routes 408
cell salvage use in Jehovah’s Witnesses
  590
central venous pressure 75, 76
cervix,
  endocervical tear 491
  postpartum pathology of 490
  priming with misoprostol 279
tears 194
  repair 195, 197
cesarean section,
  and PPH risk 141
  bleeding from uterine incision 449
  carbetocin use at 362
  causes of excessive bleeding during
  448
  classical 451
  combating hemorrhage during
  448–57
elective,
  and PPH 156
  for adherent placenta 10
  PPH after 7
  timing of 438
  emergency for unexpected adherent
  placenta 11
PPH in first stage of labor 8
European consensus on prevention
  and management of PPH at
  111
endometritis and excessive bleeding at cesarean section and 449
endometriosis 466, 469
domyometritis 495
England,
maternal morbidity 137
severe acute maternal morbidity in 501
epidemiology comparing international
PPH statistics 133–43
epidural anesthesia and anticoagulant
therapy 207
epilepsy and PPH risk 140
episiotomy,
and PPH risk 143
as cause of hemorrhage 194
for vaginal trauma treatment 4
equipment,
basic list for practical PPH training 309
preparedness for PPH 314–15
for PPH 314
ergometrine,
contraindications 114
for uterine atony 357
isolation of 355
plus oxytocin vs. oxytocin alone 103
side-effects 357
storage costs 115
use in secondary PPH 469
warning on use 66
ergot, as historical therapy 355
ergot alkaloids,
FIGO guidelines on use 612
prophylactic use of 104
vs. oxytocin 102
ergotoxin 355
esophageal Doppler 521
ethanolamine olate use with gelatin
sponge 404
ethics,
cell salvage methods in Jehovah’s
Witnesses 579
considerations in hospital-based near
miss research 151
of misoprostol use 287
use of fibrin sealants in Jehovah’s
Witnesses 475
etnicity,
PPH incidence 156
PPH risk 139
etiology,
of acute uterine inversion 185
of PPH 65, 138–9
EUPHRATES study 109–12
Europe.
B-Lynch suture compression suture
use in 438
severe acute maternal morbidity in 501
European consensus on prevention and
management of PPH 109–12
evolution and PPH 55–61
expectant management,
cf active 105
cf AMTSL 126
exsanguinating patient as a model for
PPH management 24–7
external abdominal pressure,
anti-shock 336
BMI and 336
external aortic compression device 335
external iliac artery, avoidance of
accidental ligation 446
extrinsic arteries of uterus 178
factor II, VII, IX and X (combined)
deficiency 214
factor V deficiency 213
factor V Leiden as clue to history of PPH 60
factor V and VIII (combined) deficiency
214
factor VII,
recombinant activated 359, 415–28
clinical effect 418
mechanism of action 417
pharmacokinetic studies of 417
production of 416
recommendations for use in
PPH 427–8
safety 419, 427
worldwide experience with 420–6
recombinant vs. plasma-derived 417
structure of human 416
factor VII deficiency 213
factor VIII deficiency,
and PPH 96
and secondary PPH 467
factor VIII inhibitors 206
factor X deficiency 214
factor XI deficiency 214
factor XII deficiency 214
FAST HUG approach 525
febrile non-hemolytic transfusion reaction
39
fertility,
after embolization 411
after internal iliac artery ligation 457
after placenta accreta 260
maintenance of with internal iliac
artery ligation 445
fetal anomalies and risk of placenta previa
231
fetal nutrient requirements and PPH 59
fetomaternal hemorrhage 191
fetomaternal transfusion and early
clamping 105
fibrin sealants 474–6, 480–5
method of use illustrations 478–9
patch 482
spray 482
fibrinogen,
cf cryoprecipitate 46
cf fresh frozen plasma and
cryoprecipitate 50
early use in PPH 45–7
fibrinogen replacement therapy 49
inherited abnormalities of 212
role in massive transfusion 35
use in PPH 48
fibroids,
and PPH risk 140
secondary PPH after 466
fibrosis of vesicouterine plane 265
FIGO
FIGO 2012 PPH guideline for low
resource countries 67
guidelines for PPH prevention and
treatment in 607–18
joint statement with ICM on
Management of Third Stage
of Labor to Prevent PPH 121
Index

modern teaching/learning modalities 514
for PPH management recommendations 118
for non-pneumatic anti-shock garment 318
Finland, severe acute maternal morbidity in 89–93
unplanned home deliveries in 572
FloSeal 480–5
Foley catheter 379
fondaparinux use during pregnancy 207
forceps delivery and PPH 6
France, accurate PPH rate determination 153
maternal mortality 136
severe acute maternal morbidity in 501
use of anti-shock garments in 320
fresh frozen plasma 32
fundus,
Guinea, severe acute maternal morbidity in 501
Haultian technique for acute uterine inversion 187
HIV,
HIV-associated thrombocytopenia 202
hypovolemic shock 73
as a cause of consumptive coagulopathy 205
hypotension and leukocyte depletion filters 581
hypothemia 40
as part of 'lethal triad' 24
hypovolemia-related complications 409
hypovolemic shock 73
as a cause of consumptive coagulopathy 205
G-suit 319
gelatin sponge 400, 470
gelatin–thrombin matrix 480, 482, 483
gemeprost 358
Glanzmann’s thrombasthenia 208, 415
gelatin–thrombin matrix 480, 482, 483
glue, effect on vascular system 403
fibrin sealants 474–6, 480–5
method of use illustrations for fibrin sealants 478–9
topical hemostatic agents 480–5
gravimetric method of blood loss measurement 84
guide to PPH management poster 515
guidelines,
current guidance for clinicians on ALTSL 124
FIGO 2012 PPH guideline for low resource countries 67
for PPH prevention and treatment in 607–18
for uterine-specific balloons 392
Glasgow Coma Scale 523
Guinea, severe acute maternal morbidity in 501

Haultian technique for acute uterine inversion 187
Hayman uterine compression suture 438, 453
health care infrastructure in India 542–4
heart valve prostheses 207
HELLP syndrome 40, 82
cell salvage methods in 579
severe acute maternal morbidity in 504
with pre-eclampsia 203
hematocrit, changes in and PPH classification 129
PPH definition from 155
hematoma,
estimation of size by imaging 406
management of 196–8
paravaginal 193
postpartum 194
rectus sheath 14
retropertioneal 14
secondary PPH after 466
vaginal, topical hemostatic agents for 485
hemodynamics,
changes in uterine blood flow 89–93
changes in uterus during pregnancy 177–83
during pregnancy 180–3
of pneumatic anti-shock garment use 334
prepregnancy 177–81
hemoglobin,
determination of changes in 84
restoration of levels 78
hemolytic disease of the newborn 31
hemolytic uremic syndrome 203
hemophilia 211–12
in secondary PPH 471
recombinant activated factor VII for 415
secondary PPH and 467
hemorrhagic shock
cardiovascular physiology of 332
choice of volume expansion fluid for 77
decreased recovery times with non-pneumatic anti-shock garment 323
eye recognition of 24
identification of 550
in acute uterine inversion 185
in placental abruption 230
internal iliac artery ligation for 444
stages of 74
hemostasis,
after placenta accreta surgery 269
congenital disorders of 208–10
disorders of 199–215
mechanism of by factor VII 417–18
use in Jehovah’s Witnesses 590
hemostatic dressings 25
hemostatic resuscitation 25
heparin use during pregnancy 206
heparin-induced thrombocytopenia 202
heparin and treatment with 177
heparin therapy 206
hepatitis C and litigation 530
history,
maternal mortality 545
of anti-shock garments 331
of PPH 545
previous cesarean and PPH risk 141
previous PPH and PPH risk 141, 156
therapies used for PPH 355
HIV,
cell salvage methods contraindicated by 578
HIV-associated thrombocytopenia 202
litigation 529
home deliveries 571–4
home-based life-saving skills, FIGO guidelines on use 612
hospitals,
hospital-based near miss research 150
impact of new systems on outcome 344
intensive care management of PPH 520–5
obstetric hemorrhage equipment tray in 314
out-of-hospital deliveries 571–4
preparation of, labor ward drills 305–10
preparation protocols for management of PPH 343
proposed management scheme within 343
systems for care of women with PPH 341–7
Huntington technique for acute uterine inversion 187
hydrostatic condom catheter 379
hydrostatic intrauterine balloon tamponade, FIGO guidelines on 615
hypokalemia 27
hypertension 82
malignant 533
see also pre-eclampsia
hypocalcemia 27, 40
hypofibrinogenemia 35, 212, 213
hypogastriac artery, see internal iliac artery
hypocalkemia 27, 40
hyponitrogen and leukocyte depletion filters 581
hypothemia 40
as part of 'lethal triad' 24
hypovolemia-related complications 409
hypovolemic shock 73
as a cause of consumptive coagulopathy 205
cardiovascular physiology of 332
choice of volume expansion fluid for 77
decreased recovery times with non-pneumatic anti-shock garment 323
eye recognition of 24
identification of 550
in acute uterine inversion 185
in placental abruption 230
internal iliac artery ligation for 444
stages of 74
hysterectomy 453
adherent placenta and 11
after uterine rupture 189
as treatment for S1 and S2 bleeding 7
avoidance of by having obstetric hemorrhage equipment tray 315
cf’ balloon tamponade 383
comparisons 509
consent for in management of placenta accreta 253
for supravelar hematoma 197
impact of new hospital systems on incidence 345
incidence of emergency 458
pathology of uterine specimens from 489–97
peripartum 462–4
impact of new hospital systems on incidence 346
indications for 462
severe acute maternal morbidity after 507
surgical principles of 463–4
use in Japan 171
hysterotomy for compression suture after vaginal delivery 436
POSTPARTUM HEMORRHAGE

International Collaborative Group 154
International Confederation of Midwives (ICM), joint statement with FIGO on Management of Third Stage of Labor to Prevent PPH 121
severe acute maternal morbidity in 501
surgical management of PPH 541
use of pelvic pressure pack during transport to tertiary care 460
lower genital tract bleeding 193–8
lower uterine segment, postpartum pathology of 491–3
lower uterine vascular supply, anatomy of 19–23
dissections showing 22

macrosomia 58, 140
magnetic resonance imaging (MRI), before embolization to identify placental abnormalities 406
for placenta accreta 250
guidelines for placental 17
imaging for placental invasion 267
Malawi, MamaNatalie® newborn simulator trials in 603
Mali, AMTSL in 123
maternal mortality, maternal morbidity, maternal circulation to placenta 180
massive transfusion, 602–3
Malaysia, MamaNatalie® newborn use in 325
magnetic resonance imaging (MRI), lower uterine vascular supply, lower uterine segment, postpartum bleeding 193–8
in 19th century England 355
in Africa 136
in France 136
in placenta accreta 247
in UK 135
in USA 136
inaccurate blood loss estimation 164
increase in Illinois 348
instrumental delivery 164
leading cause 55
morbidity–mortality continuum 500
non-pneumatic anti-shock garment use 325
placenta previa 163
placental abortion 162
prevention strategies in low resource settings 542–4
refusal of care and 163
release for hospital form for women refusing transfusion 600
risk in Jehovah’s Witnesses 588
uterine rupture 164
Mathew Duncan separation method 95
May–Hegglin anomaly 208
mechanical heart valve prostheses 207
medical anti-shock trousers 318
medical management of 164
termination of pregnancy using misoprostol 276
in 377, 285, 286
medical therapy 355–9
menstruation after embolization 411
methotrexate, cf mifepristone/misoprostol in placenta accreta 260
for abdominal pregnancy 386
for conservative management of placenta accreta 454
for placenta accreta 244, 253
with misoprostol for medical termination of pregnancy 276
methylergometrine, warning on use 66
Mexico, cost-effectiveness of carbetocin study in 366
non-pneumatic anti-shock garment studies in 332
microangiopathy in thrombocytopenia 202–4
microchimerism 27
midwife, care after PPH by 551
debriefing 552
documentation 551
management of PPH by 551
role in PPH prevention 549–51
training of 552
mifepristone, description 259
use in first trimester 286
use in placenta accreta 259–61
with misoprostol for medical termination of pregnancy 276
Millennium Development Goal 5 120, 284
misoprostol 4, 114, 275–80
administration route and side-effects 299
of conventional oxytocics 279
cf oxytocin 104, 284, 296
cf placebo/no uterotonic 104
chemical structure 275
community-based continuum of care use 556
cost effectiveness of 541
costs of 358
countries in which it is approved for use 70
deaths averted by 286
description 259, 275
efficacy at community level 353
existing evidence for use of 66
FIGO guidelines on 609, 612
for cervical priming 279
for uterine atony 357
labor induction 285
off-label use 284
overview of studies of its use in PPH 289–95
pharmacokinetics 275
plus oxytocin 300
recommendations for use in PPH 295
safe dose by gestation 278
safety 278
side-effects 276
sublingual for PPH 296–301
use after intrauterine fetal death 286
use by trained birth attendants 284
use for medical termination of pregnancy 276
use in first trimester 276, 285
use in low resource settings 285, 540
use in out-of-hospital deliveries 573
use in placenta accreta 259–61
use in practice 284–7
use in second trimester 277, 287
use in third stage of labor 279
use in third trimester 278, 286
mobile phone use to distribute reproductive health information 287
moda, blood loss assessment from 354
Modified Early Obstetric Warning Scores 74, 75, 359
morbid–mortality continuum 500
morbidly adherent placenta, use placenta accreta, placenta increta, placenta percreta
motor vehicle accidents and abdominal trauma 189–91
multidisciplinary teams,
and reduction of severe acute maternal morbidity 510
for placenta accreta management 251
multigate spectral Doppler analysis 89, 90
multiple gestation, placenta previa risk 231
PPH incidence 152, 156
PPH risk 140
Musokap initiative 68
myonecrosis 492

Index
National Patient Safety Agency
recommendations 166
near misses,
cf severe acute maternal morbidity 499
determining incidence 147–51
necrosis at cesarean section scar site 492
NeoNatalie® newborn simulator 603
neovascularization,
anastomotic levels of 266
in placental invasion 265
Nepal, misoprostol use in 557
Nigeria,
  blood loss assessment by moda 354
  misoprostol use in 286, 287
  non-pneumatic anti-shock garment
  trials in 322–7
  use in 559
Nitabuch’s layer 264
non-governmental organizations 543
non-pneumatic anti-shock garment 558
application 321
description of 318
FIGO guidelines on 616
for non-atomic PPH 326
intra-abdominal pressure and 338
manufacture 328
mechanisms of action 331–9
patient management in 322
pelvic blood flow and 337
physiologic studies of 335
removal 322
suggested protocol for use 320
trials 318–28
  for use during transport 327
  in Mexico 332
  in Zambia 327, 332
  in Zimbabwe 327, 332
use during transportation 315, 318, 454
use in developed countries 328
use in Egypt 322–7
use in low-resource settings 320
use in Nigeria 322–7
use in Pakistan 322
use with other therapies 327
variation in strength of appliers and
  efficacy 338–9
noradrenergic receptors 522

Obstetric Hemorrhage Education Project
348–50
obstetric hemorrhage equipment tray
314
obstetric rapid response team 342
obstructed labor and uterine rupture 188
one-step conservative surgery for placenta
  accreta 267–70
organ-dysfunction approach to maternal
  near miss 148
out-of-hospital deliveries 571–4
  global rates 572
  planned vs. unplanned 572
  PPH and 573
ovarian arteries, prepregnancy
  hemodynamics 178
ovarian vein,
  diameter decrease after pregnancy 182
  diameter increase during pregnancy 182
  oxytocin 101–4
    after successful tamponade 380
    cf carbetocin 362, 363
    cf misoprostol 104, 279, 284, 296
    efficacy 297
chemical structure 362
FIGO guidelines on use 612
for uterine atony 356–7
limitations of use 361
plus misoprostol 300
prophylactic use plus misoprostol
  301
role in third stage of labor 95
side-effects 356
synthesis 355
use in first stage management and
  PPH 157
use in secondary PPH 469
use in third stage of labor 102, 103, 104
  vs. ergometrine plus oxytocin 103
  vs. ergot alkaloids 102
  vs. no uterotonic 102
oxytocin agonists 102
packed red blood cells 30
packing 9
  for vaginal tears 195
  in hemostatic resuscitation 25
  pelvic pressure pack 458–60
  success of 459
uterine 379
Pakistan,
  misoprostol use in 557
  non-pneumatic anti-shock garment
  trials in 322
parallel blood flow circuits in uterus 181
parity,
  placenta previa risk 231
PATHOPHYSIOLOGY,
  of uterine atony 97
  of uterine muscle 94
patient safety teams 342
patient transfer 5
barriers to 559
in low resource settings 543
non-pneumatic anti-shock garment
  and 315, 318, 325, 327
problems and maternal morbidity
  and mortality 308
reduction of severe acute maternal
  morbidity and 510
pelvic anastomoses 442
pelvic pressure pack 458–60
for obstetric hemorrhage equipment
  tray 315
pelvic vascular supply 439
anatomy on imaging 399–400
pelvic vessels,
  abnormal vasculature and secondary
    PPH 467
pelvic artery embolization in
  placenta accreta 267
vascular branching patterns in 399
periungual tear repair 195
peripartum hysterectomy 462–64
impact of new hospital systems on
  incidence 346
severe acute maternal morbidity after
  507
permanent embolic materials 400
pharmacokinetics of misoprostol 275
physiology,
adaptations during pregnancy 82
  of hypovolemic shock 332
  of internal iliac artery ligation 442
placenta,
  abnormal in S1 and S2 segments 22
  adherent 10
  guidelines for MRI in 17
bipartite 236
classical methods of delivery 95
examination of 4, 119
FIGO guidelines on facilitation of
delivery 611
growth and maturation of 180
guidelines for placental MRI 17
invasive pattern of human
  placenta
totaled in and diagnosis of placenta
  accreta 241
lower segment implantation and
  PPH 97
management for abdominal
  pregnancy 585
management of morbidity 163
manual removal, EUPHRATES
  consensus on 111
maternal circulation to 180
mature 180
pathology 496
and final blood loss volume 373
rare abnormal shapes 236
removal in acute uterine inversion 186
retrained 494
retained tissue or membranes 453
retention prevalence 138
separation and uterine activity 94
success rate of 236
placenta accreta 57, 235–6
as a cause of consumptive
  coagulopathy 205
balloon catheter placement and
  embolization in 408
compression suture for 436
diagnosis 247
effect of screening on management
  in a UK hospital 247–56
elective cesarean for 10
emergency cesarean for 11
fertility after 260
imaging of 248–50
guidelines for MRI in 17
in UK 163
incidence 240
increasing 247, 263
management,
  algorithm for 243
  conservative 252
  conservative leaving placenta in
    uterus 242
  conservative with adjuvant
    therapy 244
  conservative with resection of
    placental bed 244
  emergency 244–5
  in UK 247–56
  intraoperative 254
  multidisciplinary team planning
    for 251

628
of acutely presenting cases 253
one-step conservative surgery 263–71
outpatient 251
postpartum 256
timing of surgery 267
using misoprostol/ 259–61
when diagnosed after delivery 244–5
when diagnosed antenatally 250
with hysterectomy 242
without hysterectomy 242–4
management of 240–5
maternal mortality 247
morphological classification 264
multidisciplinary team management 254
operative delivery of infant 255
pathophysiology of 98
peripartum hysterectomy and 463
postoperative thromboprophylaxis 48–51
postpartum pathology of 493
PPH incidence and 156
pregnancy after 263
prenatal screening for 240–1
preoperative checklist 254
preparation protocols for management 343
prevalence 138
recommended protocol for 410
risk factors 240, 248
secondary PPH after 466
surgical management 453
systems of neovascularization in 266
topical hemostatic agents for 485
unexpected diagnosis 11
placenta increta 235–6
balloon catheter placement in 409
compression suture for 436
prevalence 138
recommended protocol for 410
secondary PPH after 466
placenta membranacea 236
placenta percreta 57, 235–6
compression suture for 436
one-step conservative surgery 255
postpartum pathology of 493
prevalence 138
recommended protocol for 410
secondary PPH after 466
placenta previa 231–5
after cesarean section care bundle 266
as risk factor for placenta accreta 166
clinical presentation 231
compression suture for 434
diagnosis 231
imaging for 232
excessive bleeding at cesarean section and 449
grading 231
incidence 231
management, cesarean section for 234–5
expectant 233
procedure used 234
pathophysiology of 98
peripartum hysterectomy and 463
placenta accreta risk and 248
preparation protocols for management 343
risk factors for 231
substandard management 163
surgical management 453
topical hemostatic agents 480
use of fibrin sealants in 476
placental abnormalities 227–36
placental abruption 57, 227–30
after blunt abdominal trauma 190
as a cause of consumptive coagulopathy 205
concealed cf revealed 228
diagnosis 227
graduation 228
incidence 227
management, by immediate delivery 229
expectant 230
of complications 230
peripartum hysterectomy and 463
risk factors 227, 228
substandard management 162
tocolytic masking of 191
triple tourniquet for 451
placental invasion description 263–4
placental lacunae 248
placental separation mechanics 182
placental–vesical system
(neovascularization) 266
placentation,
impaired 57
invasive pattern in humans cf other primates 56
plasma,
cf cryoprecipitate and fibrinogen 50
dose 33
for transfusion 32–3
volume changes 84
platelets,
congenital platelet disorders 208
dose 34
for transfusion 33–4
pneumatic anti-shock garment 318, 319
animal studies 333
current status of 320
human studies 334
physiologic studies of 333
theoretical model of function 333
POPPHI 121–3
postpartum hemorrhage (PPH),
accurate rate determination 152–8
after elective cesarean section 7
after forceps delivery 6
algorithm for management of 196
autopsy after 496
case reports 546–8
causes 130–1
classification 82, 129–32
common scenarios 3–18
concealed 13
declining mortality in Japan 169–74
definition 64, 81, 133
early fibrinogen use 45–7
etiology 65
EUPHRATES definition 109
European consensus on prevention and management of 109–12
evolution and 55–61
history of 545
hospital systems for care of 341–7
in elective cesarean for adherent placenta 10
in failed sequential instrumental delivery/emergency cesarean 9
in other animals 58
in uterine inversion 15
instrumental delivery and 5
intensive care management 520–5
link with invasive placentation 57
litigation after 527–35
longstanding history of 60
management in low resource settings 539–44
management model 24–7
management under different scenarios 3–18
massive transfusion in 34–7
measurement methodologies 65
misoprostol therapy 279, 289–95, 296–301
modern teaching/learning modalities for PPH management 514–18
new approaches to transfusion in 48–51
obstetric hemorrhage equipment tray contents 314
pathophysiology of 97
prevention of 66
EUPHRATES consensus on 109–11
in UK 166
initiatives 67
projects in Japan 172
progressive intermittent 12
secondary 466–71
severe acute maternal morbidity 499–511
statistics 64
transfusion management of 30–41
vaginal delivery and 4
variations in definition 155
vascular malformations and 218–24
WHO guidance on prevention 121
post-surgical packing 458
post-transfusion purpura 27
PRactical Obstetric MultiProfessional Training (PROMPT) 565
pre-eclampsia 57, 82
and HELLP syndrome 203
and PPH risk 140
as a cause of consumptive coagulopathy 205
pregnancy,
after placenta accreta 263
changes in coagulation system during 199
uterine arteries during 182
preterm labor after blunt abdominal trauma 190
prevention initiatives 67
Prevention of PPH Initiative 121–3
previous PPH and PPH incidence 156
professional organizations, role in PPH prevention 67
progressive intermittent PPH 12
prolonged pregnancy and PPH risk 140
prophylaxis,
antibiotic use and pelvic packing 460
antibiotic use in placenta accreta 252
for deep vein thrombosis after placenta accreta surgery 270
internal iliac artery ligation for 442
misporel use after prophylactic
oxytocin 301
non-pneumatic anti-shock garment
use in 559
thromboprophylaxis in placenta
accrata 256
use of ergot alkaloids in third stage of
labor 104
prostaglandin,
excessive bleeding at cesarean section
and 449
for uterine atony 358
injectable 104
isolation of 355
see also misoprostol
use in third stage of labor 96, 104
pseudoaneurysm 218
angiographic proof 222, 223, 471
dult causes 222
of uterine artery 13
pulmonary edema 409
pulmonary embolism 356
pulmonary embolism, for PPH 139–43, 539
for placental abruption 227, 228
for placenta accreta 247, 263
for placenta previa 231
for placental abruption 227, 228
for PPH 139–43, 539
changes in 157
classic factors cf recent findings
157
for secondary PPH 467
for severe acute maternal morbidity
505
for tamponade test 392
for uterine atony 356
identification of by midwife 549
importance in out-of-hospital
delivers 571
increased PPH incidence and 152
primary prevention and severe acute
maternal morbidity 508
Royal College of Obstetricians and
Gynaecologists (RCOG),
guidelines for use of intrarui
terine balloon 385
management recommendations 551
standards for prevention and
treatment of PPH 166
rupture, see uterine rupture
rural deliveries, blood loss assessment in
86
Rüsch hydrostatic urological balloon
378
experience in Italy 382
S1 segment 6
abnormal placentation in 22
placental invasion 267
uterovaginal blood supply 19–23
S2 segment 6
abnormal placentation in 22
placental invasion 267
segment of uterovaginal blood
supply 19–23
safety,
of cell salvage methods in obstetrics
578
of fibrin sealants 475
of recombinant activated factor VII
419, 427
scenario teaching 309–10
Schultze method 95
sciatica 410
Scotland,
maternal morbidity 136
severe acute maternal morbidity in
501, 507
screening,
effect on placenta accreta
management in a UK
hospital 247–56
for morbidly adherent placentas 250
for placenta accreta 250
prenatal screening for placenta
accrata 240–1
sealants 474–6
secondary autoimmune
trombocytopenia 201
secondary PPH 466–71
causes 467
management 468
resuscitation 468
risk factors for 467
Sengstaken–Blakemore tube 378, 381
sepsis,
after tamponade 383
as a cause of consumptive
coagulopathy 205
periapartum hysterectomy and 463
severe acute maternal morbidity in
504
septicaemia 37
septic transfusion reaction 37
severe acute maternal morbidity 147–51,
499–511
attributed to hemorrhage 505
near miss 499
definition 499
identification of 501
incidence 501
increasing incidence 506
main causes 504
measures to reduce 508–11
mortality and 501
outcomes after 508
risk factors for 505
sexual intercourse avoidance in placenta
accrata 251
Sheehan syndrome 533
shivering and misoprostol 289
shock,
cardiovascular physiology of 332
decreased recovery times with
non-pneumatic anti-shock
garment 323
identification of 550
in acute uterine inversion 185
in placental abruption 230
internal iliac artery ligation for 444
stages of 74
shock index 335
side-effects,
of blood transfusions 587
of carbetocin 364, 366
of carboestrogen 357
of ergometrine 115, 357
of misoprostol 299, 356
of oxytocin lack of 115
safety of fibrin sealants 475
skills teaching 308–9
sample scenario for PPH due to
uterine atony 312
sample scenario for PPH not due to
uterine atony 313
stations in training 349
training and reduction of severe
acutie maternal morbidity 510
smoking and risk of placenta previa 231
South Africa,
severe acute maternal morbidity in
501, 501
South America, B-Lynch suture
compression suture use in 438
statistics,
first national register of 64
for PPH incidence and risk factors
133–43
how to measure PPH 65
stepwise devascularization 439–40, 452
in major PPH 20
subinvolution 494
secondary PPH after 466
substandard care 3
substandard management,
of placenta previa 163
of placental abruption 162
of PPH 163
suplrophene use in placenta accreta
management 244
suprarelevator hematoma 197
trials for non-pneumatic anti-shock garment use during 327
trauma 185–91
anti-shock garments for 318–20
blunt abdominal trauma 189–91
prevalence 138
trial of labor 189
triple tourniquet technique 451
trophoblast invasion,
patterns of 56
placenta previa and 98
PPH and 58
pre-eclampsia and 57
trophoblastic disease 495

UK,
accurate PPH rate determination 153
algorithm for PPH management 167
maternal mortality 135
from PPH in 162–7
placenta accreta management in 247–56
severe acute maternal morbidity in England and Scotland 501
unplanned home deliveries in 572
use of cell salvage methods in 579–80
ultrasound,
abdominal pregnancy diagnosis 584
Bakri balloon 375
before embolization 406
diagnosis of placenta previa by 232
Doppler imaging,
for placenta accreta 248, 249
for vascular malformations 219, 220, 221
placenta accreta diagnosis 247, 248
pregnancy screening for 240–1
portable machine 91
three-dimensional,
color power Doppler for placenta accreta 249
for placenta accreta 249
vascular supply of pelvis 399–400
umbilical cord,
clamping recommendations 115
delayed clamping 118
early clamping of 105
FIGO guidelines on management 611
see also controlled cord traction
unlawful practice of medicine 527
uterine damage during internal iliac artery ligation 446
injury to 5
stenting of in placenta accreta 254
US Agency for International Development, POPPHI 121–3
USA,
accurate PPH rate determination 154
B-Lynch suture compression suture use in 438
development of hospital systems for PPH in New York 342–7
Illinois model of training 348–50
maternal morbidity 137
maternal mortality 136
planned home deliveries in 572
severe acute maternal morbidity in 501, 507
topical hemostatic agent use in 484
uterine activity and placental separation 94
uterine anastomotic system 267
uterine arteries,
anastomosis with vaginal arteries 20
bilateral embolization 470
blood flow, at term 181
branching patterns 399
diameter increase during pregnancy 181
effect of balloon tamponade on 375
embolization in placenta accreta management 244
fetal nourishment and 180
ligation 452
multigate spectral Doppler analysis 90
prepregnancy hemodynamics 177
pseudoaneurysm 13
segmental concept of anatomy 19
uterine atony,
after elective cesarean section 8
approaches to 381
Bakri balloon for 387
carbocetin for 361
carboprost for 357
cf vaginal trauma 5
community-level management 353
eMBOLization and balloon catheter placement 398
ergometrine for 357
identification 355
in vaginal delivery PPH 4
intraluminal pressure readings in 369
medical therapies 355
medical therapy for 355–359
misoprostol cf oxytocin for 296
misoprostol for 357
oxytocin for 356–7
pathophysiology of 97
peripartum hysterectomy and 463
postpartum pathology 495
prevalence 138
prostaglandins for 358
recombinant factor VII 415
risk factors for 356
S1 bleeding and 6
sample scenarios for training 312, 313
secondary PPH after 466
surgical steps to arrest 451
tamponade for 377, 381
underlying causes 58
uterine blood flow,
hemodynamic changes in 89–93
quality Doppler profile 91, 92
uterine embolization, anatomic reasons for failure 20
uterine inversion,
hydrostatic repositioning 16
manual repositioning 15
PPH in 15
uterine massage 116, 119
FIGO guidelines on 610
injection of mother in self-massage 119
uterine muscle,
contraction and control of bleeding 95
Index

wall structure and compliance with tamponade 374
vagina, bleeding from lower genital tract 193–8
examination for trauma 4, 5
vaginal arteries, anastomoses with uterine arteries 20
vaginal delivery, carbetocin use at 363
European consensus on prevention and management of PPH at 110
hysterotomy for compression suture after 436
PPH incidence 156
PPH scenario 4
vaginal hematoma, topical hemostatic agents for 485
vaginal trauma, after ventouse delivery 5
as cause of PPH 4
prevalence 138
repair 195
secondary PPH after 466
variant Creutzfeldt–Jakob disease 587
vascular malformations, clinical presentation 219
diagnosis 219
management 220
PPH and 218–24
prevention of 222
types 218
vasopressors 522
venous thromboembolism, anticoagulant therapy during pregnancy and peripartum 206–8
ventilation, invasive 521
non-invasive 521
ventouse delivery, incorrect cup placement 6
PPH scenario 5
related lacerations 5
vesicouterine system (neovascularization) 266
visual assessment of PPH 71, 82
visual estimation of blood loss 71, 134
vitamin K metabolism deficiency 214
volume deficit classification 130
volume overload 40
volume resuscitation 45
von Willebrand disease 96, 208–10
and PPH risk 140
in secondary PPH 467, 471
warfarin 207
WHO, guidance on management of third stage of labor 121
modern teaching/learning modalities for PPH management 514
recommendations 118
terminology for near misses 147
terminology for severe acute maternal morbidity 504
World Maternal Antifibrinolytic Trial 359
wound dehiscence and secondary PPH 467
Zambia, blood loss assessment by chittengue 354
non-pneumatic anti-shock garment trials in 327, 332
Zanzibar, MamaNatalie® newborn simulator trials 603
Zimbabwe, non-pneumatic anti-shock garment trials in 327, 332